Kymera Therapeutics Inc. (KYMR) Social Stream



Kymera Therapeutics Inc. (KYMR): $23.66

2.56 (+12.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KYMR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Kymera Therapeutics Inc (KYMR) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering KYMR.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-03 10 $85 $67 $77.5 $43.31 78.94%
2022-02-24 11 $91 $62 $77 $43.31 77.79%
2022-02-28 11 $91 $62 $74.222 $43.31 71.37%
2022-03-02 11 $91 $62 $74 $43.31 70.86%
2022-03-10 12 $91 $44 $71 $43.31 63.93%

The Trend in the Analyst Price Target


KYMR's average price target has moved down $5.43 over the prior 30 weeks.

Over the past 49 weeks, KYMR's average upside potential has been 50.61%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 3 85 65 76.80 38.44 99.79%
2021-04-08 3 85 65 76.80 34.99 119.49%
2021-08-24 7 85 65 76.29 54.91 38.94%
2021-09-20 8 85 68 78.43 60.49 29.66%
2021-11-12 10 85 67 77.50 62.89 23.23%

KYMR Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.5 9 0 3 0 0 12

The Trend in the Broker Recommendations


KYMR's average broker recommendation rating improved by 0.64 over the prior 26 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KYMR as an investment opportunity.

  • In the context of stocks in the mid market cap category, Kymera Therapeutics Inc's number of analysts covering the stock is higher than 506.02% of them.
  • In terms of how Kymera Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 486.08% of that group.
  • KYMR has a greater upside potential (average analyst target price relative to current price) than 447.69% of stocks in the mid market cap category.
  • KYMR has a lower variance in analysts' estimates than -95.19% of Pharmaceutical Products stocks.

In the Pharmaceutical Products industry, KOD, IOVA, and IMVT are the three stocks most similar to Kymera Therapeutics Inc regarding the price target and analyst recommendation information presented here.

What is the outlook for KYMR? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5583 seconds.